1. Home
  2. KE vs IMMX Comparison

KE vs IMMX Comparison

Compare KE & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimball Electronics Inc.

KE

Kimball Electronics Inc.

HOLD

Current Price

$25.17

Market Cap

635.4M

Sector

Technology

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$9.97

Market Cap

629.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KE
IMMX
Founded
1961
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
635.4M
629.3M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
KE
IMMX
Price
$25.17
$9.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$28.00
$19.20
AVG Volume (30 Days)
174.8K
1.6M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.78
N/A
Revenue
$1,486,727,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.57
N/A
P/E Ratio
$33.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.04
$1.94
52 Week High
$33.19
$11.61

Technical Indicators

Market Signals
Indicator
KE
IMMX
Relative Strength Index (RSI) 49.72 64.47
Support Level $23.54 $7.99
Resistance Level $26.91 $10.61
Average True Range (ATR) 1.23 0.70
MACD 0.02 0.20
Stochastic Oscillator 53.47 95.51

Price Performance

Historical Comparison
KE
IMMX

About KE Kimball Electronics Inc.

Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: